B7-H3-Targeted Immunotherapy: a Competitor Analysis

This competitive intelligence report about B7-H3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting B7-H3 (or CD276) as of August of 2025.

B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in a wide range of cancer types, including lung, prostate and esophageal, and its overexpression has been shown to correlate with poor prognosis in some cancers, making B7-H3 a promising therapeutic target. At the same time, B7-H3 is expressed at a low level in normal tissues. In malignant tissues, B7-H3 inhibits tumor antigen-specific immune responses, resulting in a protumorigenic effect. Additionally, B7-H3 promotes migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and affects tumor cell metabolism.

There are no B7-H3 directed medicines approved for the treatment of any cancer, but a number of effector-enhanced B7-H3-targeted immunotherapy candidates in preclinical and clinical development. More than 15 product candidates are in clinical development, with several already in clinical phase III. B7-H3 is an ideal target for antibody drug conjugates (ADC). Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models.

This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour.

The pdf report includes a compilation of active projects in research and development of B7-H3-targeted product candidates.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced with hyperlinks to the source of information.